Edition:
India

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

10.94USD
23 Jan 2018
Change (% chg)

$1.37 (+14.32%)
Prev Close
$9.57
Open
$9.75
Day's High
$11.14
Day's Low
$9.75
Volume
383,350
Avg. Vol
76,118
52-wk High
$11.14
52-wk Low
$2.43

Latest Key Developments (Source: Significant Developments)

Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Dicerna Pharmaceuticals Inc ::ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017.  Full Article

RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Dicerna Pharmaceuticals Inc ::RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING.RA CAPITAL MANAGEMENT LLC PREVIOUSLY REPORTED 19.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 13.RA CAPITAL MANAGEMENT -ON DEC 18,ALL DICERNA PHARMA SHARES OF REDEEMABLE CONVERTIBLE PREFERRED STOCK HELD BY RA CAPITAL WERE CONVERTED INTO COMMON STOCK.  Full Article

Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Bain Capital Life Sciences Fund L.P::BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING.BAIN CAPITAL LIFE SCIENCES FUND L.P. HAD PREVIOUSLY REPORTED 26.4 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON SEPT 15.BAIN CAPITAL LIFE SCIENCES-ON DEC 18,ALL DICERNA PHARMA SHARES OF REDEEMABLE CONVERTIBLE PREFERRED STOCK HELD BY BAIN WERE CONVERTED INTO COMMON STOCK.  Full Article

Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.71 MILLION COMMON SHARES PRICED AT $7.00PER SHARE.  Full Article

Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING.  Full Article

Dicerna announces proposed public offering of common stock
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS.  Full Article

Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA.DICERNA PHARMACEUTICALS - ANTICIPATES THAT HUMAN PROOF-OF-CONCEPT DATA FROM PHASE 1 TRIAL FOR DCR-PHXC WILL BE AVAILABLE IN SECOND HALF OF 2018.  Full Article

Dicerna Pharmaceuticals Q3 loss per share ‍$0.92
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Dicerna Pharmaceuticals Inc :Q3 2017 loss per share ‍$0.92.  Full Article

Boehringer, Dicerna collaborate to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Dicerna Pharmaceuticals Inc :Boehringer Ingelheim and Dicerna announce collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis (NASH).Dicerna Pharmaceuticals Inc - ‍under terms of agreement, Dicerna may receive more than $200 million from Boehringer Ingelheim​.Dicerna Pharmaceuticals Inc - ‍Dicerna is also eligible to receive royalties staggered up to double-digits on worldwide net sales​.  Full Article

Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Dicerna Pharmaceuticals Inc : :Dicerna files clinical trial application for DCR-PHXC, the company’s most advanced GalXC™ product candidate, for phase 1 study in primary hyperoxaluria (ph).Dicerna Pharmaceuticals Inc - ‍company expects to initiate clinical dosing in Q1 2018​.Dicerna Pharmaceuticals Inc - ‍company plans to submit additional CTAS in other European countries later this year​.  Full Article

BRIEF-Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals

* ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017 Source text: (http://bit.ly/2Ac7p5t) Further company coverage: